These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 33536294)

  • 21. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Franke MF; Khan P; Hewison C; Khan U; Huerga H; Seung KJ; Rich ML; Zarli K; Samieva N; Oyewusi L; Nair P; Mudassar M; Melikyan N; Lenggogeni P; Lecca L; Kumsa A; Khan M; Islam S; Hussein K; Docteur W; Chumburidze N; Berikova E; Atshemyan H; Atwood S; Alam M; Ahmed S; Bastard M; Mitnick CD
    Am J Respir Crit Care Med; 2021 Jan; 203(1):111-119. PubMed ID: 32706644
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical application of whole-genome sequencing in the management of extensively drug-resistant tuberculosis: a case report.
    Katale BZ; Rofael S; Elton L; Mbugi EV; Mpagama SG; Mtunga D; Mafie MG; Mbelele PM; Williams C; Mvungi HC; Williams R; Saku GA; Ruta JA; McHugh TD; Matee MI
    Ann Clin Microbiol Antimicrob; 2024 Aug; 23(1):76. PubMed ID: 39175078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Bacterial Load Assay Concurs with Culture on NaOH-Induced Loss of Mycobacterium tuberculosis Viability.
    Mtafya B; Sabiiti W; Sabi I; John J; Sichone E; Ntinginya NE; Gillespie SH
    J Clin Microbiol; 2019 Jul; 57(7):. PubMed ID: 31018981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
    Gao M; Gao J; Xie L; Wu G; Chen W; Chen Y; Pei Y; Li G; Liu Y; Shu W; Fan L; Wu Q; Du J; Chen X; Tang P; Xiong Y; Li M; Cai Q; Jin L; Mei Z; Pang Y; Li L
    Clin Microbiol Infect; 2021 Apr; 27(4):597-602. PubMed ID: 32553880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen.
    Singh S; Gumbo T; Alffenaar JW; Boorgula GD; Shankar P; Thomas TA; Dheda K; Malinga L; Raj P; Aryal S; Srivastava S
    Int J Antimicrob Agents; 2023 Dec; 62(6):106968. PubMed ID: 37726063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of bedaquiline containing all oral longer regimens in treating multidrug/rifampicin resistant tuberculosis in Pakistan.
    Khan A; Khan AH; Ahmad N; Ghafoor A
    J Infect Public Health; 2024 Sep; 17(9):102522. PubMed ID: 39173557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens.
    Kempker RR; Mikiashvili L; Zhao Y; Benkeser D; Barbakadze K; Bablishvili N; Avaliani Z; Peloquin CA; Blumberg HM; Kipiani M
    Clin Infect Dis; 2020 Dec; 71(9):2336-2344. PubMed ID: 31712809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.
    Veziris N; Ibrahim M; Lounis N; Andries K; Jarlier V
    PLoS One; 2011 Mar; 6(3):e17556. PubMed ID: 21408613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis.
    Tanneau L; Karlsson MO; Svensson EM
    Br J Clin Pharmacol; 2020 May; 86(5):913-922. PubMed ID: 31840278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline.
    Setyawan MF; Mertaniasih NM; Soedarsono S
    Acta Med Indones; 2023 Oct; 55(4):430-439. PubMed ID: 38213049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
    Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence of bedaquiline resistance in a high tuberculosis burden country.
    Chesov E; Chesov D; Maurer FP; Andres S; Utpatel C; Barilar I; Donica A; Reimann M; Niemann S; Lange C; Crudu V; Heyckendorf J; Merker M
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34503982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case of primary multidrug-resistant pulmonary tuberculosis with high minimum inhibitory concentration value for bedaquiline.
    Kobayashi M; Motoki Y; Yamagishi T; Hirano H; Nonaka M; Aono A; Mitarai S; Saito T
    J Infect Chemother; 2022 Aug; 28(8):1193-1197. PubMed ID: 35550867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment Outcomes of Patients Switching From an Injectable Drug to Bedaquiline During Short Standardized Treatment for Multidrug-resistant Tuberculosis in Mozambique.
    Bastard M; Molfino L; Mutaquiha C; Galindo MA; Zindoga P; Vaz D; Mahinça I; DuCros P; Rusch B; Telnov A
    Clin Infect Dis; 2019 Oct; 69(10):1809-1811. PubMed ID: 30901021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
    Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB
    Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
    Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
    Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bedaquiline for the treatment of pulmonary, multidrug-resistant tuberculosis in adults.
    Gras J
    Drugs Today (Barc); 2013 Jun; 49(6):353-61. PubMed ID: 23807939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Twenty-four-week interim outcomes of bedaquiline-containing regimens in treatment of adolescents with rifampicin-resistant tuberculosis: A retrospective cohort study in China.
    Wu HY; Tian Y; Wang XD; Sun JS; Fan LC; Chen MX; Li R; Chen Y
    J Paediatr Child Health; 2022 Jan; 58(1):116-121. PubMed ID: 34323328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.